Hubungan Erythromycin dan Antibiotik Makrolid Lainnya dengan Malformasi Kongenital

Oleh :

dr.Saphira Evani

Erythromycin dan antibiotik makrolida lain, seperti azithromycin dan clarythromycin, sering dikaitkan dengan malformasi kongenital. Antibiotik golongan makrolida memang telah terbukti efektif untuk menangani berbagai infeksi bakteri dalam kehamilan. Namun, studi mengenai keamanan pemberian makrolida pada ibu hamil masih menunjukkan hasil yang inkonsisten.[1-4]

Beberapa studi terdahulu menunjukkan adanya hubungan konsumsi makrolida saat kehamilan dengan malformasi kongenital, khususnya defek jantung kongenital dan stenosis pilorus. Namun, beberapa studi lain melaporkan tidak ada peningkatan risiko signifikan malformasi kongenital akibat pemberian makrolida selama kehamilan.[1,4-6]

Pertanyaan mengenai keamanan pemberian makrolida pada ibu hamil kembali muncul ketika studi tahun 2020, dengan sampel besar yang dipublikasi British Medical Journal (BMJ), menunjukkan adanya hubungan antara pemberian makrolida selama kehamilan dengan risiko malformasi kongenital yang lebih tinggi dibandingkan antibiotik penicillin.[7]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Lin KJ, Mitchell AA, et al. Safety of macrolides during pregnancy. Am J Obstet Gynecol. 2013;208(3):221.e1-221.e8.
2. Mitchell AA, Gilboa SM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am J Obstet Gynecol. 2011;205:51, e1–8.
3. Crider KS, Cleves MA,et al. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163:978–985.
4. Kallen BA, Otterblad Olausson P, Danielsson BR. Is erythromycin therapy teratogenic in humans? Reprod Toxicol. 2005;20:209–214.
5. Mahon BE, Rosenman MB, Kleiman MB. Maternal and infant use of erythromycin and other macrolide antibiotics as risk factors for infantile hypertrophic pyloric stenosis. J Pediatr. 2001;139:380–384.
6. Cooper WO, Hernandez-Diaz S, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol. 2009;23:18–28.
7. Fan H, Gilbert R, et al. Association between macrolide antibiotics prescribing durin pregnancy and adverse child outcomes in the UK: population based cohort study. BMJ. 2020;368:m331. https://www.bmj.com/content/368/bmj.m331
8. Drugs.com. Azithromycin pregnancy and breastfeeding warnings. 2019. https://www.drugs.com/pregnancy/azithromycin.html
9. Heikkinen T, Laine K, et al. The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. Br. J. Obstet. Gynaecol. 2000;107:770–775
10. Therapeutic Goods Administration. Prescribing medicines in pregnancy. 2020. https://www.tga.gov.au/prescribing-medicines-pregnancy-database
11. Centers for Disease Control and Prevention. Chlamydial infections. 2015. https://www.cdc.gov/std/tg2015/chlamydia.htm#spec-con
12. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines. 2015. https://www.cdc.gov/mmwr/pdf/rr/rr6403.pdf
13. Mandell LA, Wunderink RG, et al. Infectious Diseases Society of America/ American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clinical Infectious Diseases. 2007;44:S27-72. https://www.thoracic.org/statements/resources/mtpi/idsaats-cap.pdf
14. National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing. 2019. https://www.nice.org.uk/guidance/ng138/chapter/Recommendations#treatment-for-adults-young-people-and-children
15. Bar-Oz B, Weber-Schoendorger C, et al. The outcomes of pregnancy in women exposed to the new macrolides in the first trimester: A prospective, multicentre, observational study. Drug Saf. 2012;35(7):589-598.
16. Dinur AB, Koren G, Matok I, et al. Fetal safety of macrolides. Antimicrob Agents Chemother. 2013;57(7):3307:3311. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3697347/#B10
17. Berard A, Sheehy O, et al. Use of macrolides during pregnancy and the risk of birth defects: A population-based study. Pharmacoepidemiol Drug Saf. 2015;24(12):1241-1248.
18. Kallen BAJ, Olausson PO. Maternal drug use in early pregnancy and infant cardiovascular deffect. Reprod Toxicol. 2003;17(3):255-261.
19. Kallen B, Danielsson BR. Fetal safety of erythromycin. An update of Swedish data. Eur J Clin Pharmacol. 2014;70:355-360.
20. Muanda FT, Sheehy O, Berard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017;83:2557-2571.
21. Leke AZ, Dolk H, et al. Macrolide and lincosamide antibiotic exposure in the first trimester of pregnancy and risk of congenital anomaly: A European case-control study. Reprod Toxicol. 2021 Mar;100:101-108. doi: 10.1016/j.reprotox.2021.01.006. Epub 2021 Jan 14. PMID: 33454317.